IO Biotech Announces Business Update – IO Biotech (NASDAQ:IOBT)
Independent Data Monitoring Committee Recommends Company’s Phase 3 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab in First-Line Patients with Advanced Melanoma Continued With No Modifications;